Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Forsøget er et første-i-menneske, fase I, åbent, dosiseskalerende forsøg til vurdering af sikkerheden og tolerabiliteten af ​​ES2B-C001 kombineret med montanid eller uden montanid hos patienter med human epidermal vækstfaktorreceptor 2 (HER2) Udtrykker metastatisk brystkræft

15. september 2026 opdateret af: ExpreS2ion Biotechnologies

Et første-i-menneskeligt fase I, åbent, dosis-eskalerende forsøg til vurdering af sikkerhed, tolerabilitet og immunogenicitet/foreløbig antitumoraktivitet af ES2B-C001 med eller uden montanid i HER2-udtrykkende metastatisk brystkræft

The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Graz, Østrig
        • Medical University of Graz
      • Linz, Østrig, 4010
        • Ordensklinikum Linz GmbH Barmherzige Schwestern
      • Vienna, Østrig, 1090
        • Medical University Of Vienna

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients aged ≥18 years at screening visit.
  • Diagnosis of HER2-expressing locally advanced, unresectable, or metastatic BC, with HER2 IHC level 1+, 2+ (either FISH negative or positive), or IHC level 3+, after undergoing 2-3 lines of anticancer therapy.
  • Life expectancy of at least 3 months.
  • ECOG performance status 0-2.
  • Patients have adequate bone marrow, kidney, liver, heart, and lung function without clinically significant laboratory parameters as judged by the investigator.
  • 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140 ms, or evidence of prior infarction.
  • Recovered from side effects, adverse reactions, or adverse events due to prior therapy and/or surgery; any residual toxicities and toxicities related to current anticancer treatment must be ≤ Grade 2, except for alopecia, neuropathy or lymphoedema.
  • If female, non-pregnant, postmenopausal, or practicing reliable contraception.
  • If male, sterilized or using reliable contraception.

Exclusion Criteria:

  • Any planned intravenous chemotherapy regimens or check point inhibitors, or previous therapy with those agents during the past 1 month and the patients are neutropenic. Maintenance therapy with a stable dose of HER2-directed mAbs or treatment with antibody drug conjugates (ADCs) for metastatic BC is allowed at the discretion of the treating physician.
  • Symptomatic CNS metastatic disease requiring treatment with high dose steroids (i.e., above 10 mg of prednisone or equivalent) within 14 days prior to first administration of ES2B-C001 (with or without adjuvant).
  • Concurrent or recent (within 21 days or 5 half-lives) involvement in any other clinical trial with an investigational drug, device, or other experimental intervention.
  • Concomitant severe or uncontrolled underlying medical and/or mental disease unrelated to the tumor, which in the opinion of the investigator is likely to compromise patient safety and affect the trial's outcome.
  • Previous documented coronary artery disease or congestive heart failure (>NYHA II).
  • Echocardiography with LVEF <50%.
  • Uncontrolled hypertension.
  • Active, known, or suspected autoimmune disease, except thyroid conditions sufficiently controlled on thyroid hormone therapy, and controlled insulin dependent diabetes.
  • Necessity for long-term immunosuppression (≤ 4 mg dexamethasone may be used transiently).
  • Systemic infection requiring intravenous antibiotics within 14 days before dosing.
  • Chronic use of anti-viral agents, except for human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV) treatments.
  • History of severe hypersensitivity reactions to any of the trial drug components.
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Note: Administration of inactivated or recombinant vaccines/killed vaccines are allowed.
  • Birthmarks, tattoos, wounds, or skin conditions on deltoid region/buttocks that may obscure the assessment of injection site reactions.
  • Female patients who are pregnant, or lactating.
  • Any infection (including SARS-CoV-2), that in the opinion of the investigator would, upon inclusion in the trial, lead to potentially harming patients' safety or integrity.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Kohort C1: 50 ug ES2B-C001 med [adjuvans]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Eksperimentel: Kohort C2: 150 ug ES2B-C001 med [Adjuvans]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Eksperimentel: Cohort C3: 450µg ES2B-C001 med eller uden [adjuvant]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To determine the safety, tolerability, maximum tolerated dose (MTD) for ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18
  • Nature and frequency of dose-limiting toxicities (DLTs).
  • Incidence, nature and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
  • Incidence, nature and severity of injection site reactions according to FDA Guidance on Toxicity Grading Scales in Vaccine Trials (FDA, 2007).
From enrolment to the end of study at week 18

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18

Immunogenicity as humoral immune response: Total anti-HER2 Immunoglobulin G (IgG) and IgG lambda titers in sera by enzyme-linked immunosorbent assay (ELISA).

From enrolment to the end of study at week 18

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Percentage of patients with measurable disease at baseline achieving Complete Remission (CR) or Partial Response (PR) according to RECIST 1.1 as assessed by the investigator during routine follow up.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Percentage of patients with Disease Control Rate (DCR) according to RECIST 1.1 as assessed by the investigator during routine follow up.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Progression free survival (PFS) in patients with Stable Disease (SD), or PR, at the time of first dosing of ES2B-C001 alone or in combination with [adjuvant] according to RECIST 1.1.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Overall survival (OS)

From enrolment to the end of study at week 18
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18

Optionally, other immunogenicity and biomarker readouts: characterization of anti-HER2 immunoglobulins in selected sera, including isotyping (e.g. IgM, IgG and IgG subclasses IgG1-4, IgD, IgE, IgA); analysis of HER2 epitope recognition profiles; cellular immune responses; in vitro cell stimulation assays; and measuring circulating tumor DNA.

From enrolment to the end of study at week 18

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Thomas K. Jorgensen, ExpreS2ion Biotechnologies

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. juni 2025

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

1. september 2028

Datoer for studieregistrering

Først indsendt

12. december 2024

Først indsendt, der opfyldte QC-kriterier

17. december 2024

Først opslået (Faktiske)

24. december 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ES2B-C001-S01
  • 2024-516333-12-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Within the study de-identified patient data will be shared with

  • the operational study team, sponsor, auditor and for reporting of safety events to the regulatory agencies and EC
  • Data Monitoring Committees/ or other independent committees during the study
  • At the end - data listings are part of the Appendices of the CSR which will be shared to regulatory agencies and EC

IPD-deling Understøttende informationstype

  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner